Tag Archive for: US FDA Approval

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application Phase II trial expected to begin Q1 2024 in up to 160 patients with acute kidney injury (AKI) following cardiac surgery Cambridge, UK – December 14, 2023 – Mission Therapeutics (“Mission” […]

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

NephroScan is now US FDA approved for the preparation of Tc-99m DMSA NephroScan aids in the detection of kidney cortical defects in adult and pediatric patients, including term neonates GE Healthcare to commence distribution in the US Manufactured by ROTOP Pharmaka in Germany LONDON, UK, 23 February 2022 – Theragnostics announces that NephroScan, its radiodiagnostic imaging drug used […]